search
Back to results

Clinical Trial of EPASS With Hot AXIOS System (PASSAGE)

Primary Purpose

Gastric Outlet Obstruction

Status
Recruiting
Phase
Not Applicable
Locations
Japan
Study Type
Interventional
Intervention
Hot AXIOS system used for EPASS
Sponsored by
Boston Scientific Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Gastric Outlet Obstruction

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Unresectable malignant duodenal obstruction confirmed by biopsy Eligible for endoscopic intervention GOOSS score of 0 or 1 18 years of age or older Willing and able to comply with the study procedures or legally authorized representative (LAR) must provide written informed consent form (ICF) to participate in the study Exclusion Criteria: GOO symptoms are not expected to improve after the index procedure Life expectancy is about 3 months or less, which is not assumed applicable for surgical GJ Prior metallic stent placement for GOO Contraindicated to surgery and general anesthesia Neoplasm invading the target site of puncture in gastric and/or jejunum Abnormal coagulation INR > 1.5 and not correctable (per the discretion of the physician) or who require continuous complete anticoagulation Bleeding diathesis Altered anatomy of the upper gastrointestinal tract due to surgery of esophagus, stomach and duodenum that might preclude endoscopic drainage Presence of ileus caused by peritoneal carcinomatosis, or expected to present within 30 days post procedure Intervening gastric varices or vessels at the target site of stent insertion Ascites that may interfere the safety of the index procedure Biliary tract obstruction requiring treatment at the same day of the index procedure Allergic to any of the device materials Contraindications to use of electrosurgical devices Pregnancy, breastfeeding or intending to become pregnant during the study period Subject is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the study sponsor) Vulnerable subject Subject has other reason not to be eligible for this study per investigators' discretion Guidewire doesn't cross the area of GOO EP-DB doesn't advance to the target site in jejunum The distance between the gastric wall and jejunal wall when visualized on ultrasound after saline is introduced into the space between the two inflated balloons of EP-DB is deemed about 2 cm or more

Sites / Locations

  • Aichi Cancer Center HospitalRecruiting
  • Teine Keijinkai HospitalRecruiting
  • Saitama Medical University International Medical CenterRecruiting
  • The University of Tokyo HospitalRecruiting
  • Cancer Institute Hospital of JFCRRecruiting
  • Tokyo Medical University HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Hot AXIOS system

Arm Description

Hot AXIOS system (20 mm diameter stent)

Outcomes

Primary Outcome Measures

GOOSS 3 rate without MAE
GOOSS 3 rate without MAE

Secondary Outcome Measures

Full Information

First Posted
December 1, 2022
Last Updated
September 24, 2023
Sponsor
Boston Scientific Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT05644951
Brief Title
Clinical Trial of EPASS With Hot AXIOS System
Acronym
PASSAGE
Official Title
A Prospective, Multi-center, Single-arm Study for Unresectable Malignant Gastric Outlet Obstruction With EUS-guided Double-balloon-occluded Gastrojejunostomy Bypass
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 23, 2022 (Actual)
Primary Completion Date
March 31, 2024 (Anticipated)
Study Completion Date
October 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boston Scientific Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A prospective, multi-center, single-arm study for unresectable malignant gastric outlet obstruction with EUS-guided double-balloon-occluded gastrojejunostomy bypass (EPASS)
Detailed Description
Primary objective is to investigate the safety and effectiveness of the AXIOS™ lumen-apposing Metal Stent used in the EUS-guided double-balloon-occluded gastrojejunostomy bypass (EPASS) for the management of symptoms associated with gastric outlet obstruction (GOO) secondary to malignant unresectable neoplasm. Primary Endpoint is GOOSS 3 rate without MAE at 30 days post procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Outlet Obstruction

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
51 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Hot AXIOS system
Arm Type
Experimental
Arm Description
Hot AXIOS system (20 mm diameter stent)
Intervention Type
Device
Intervention Name(s)
Hot AXIOS system used for EPASS
Intervention Description
EUS-guided double-balloon-occluded gastrojejunostomy bypass with Hot AXIOS system
Primary Outcome Measure Information:
Title
GOOSS 3 rate without MAE
Description
GOOSS 3 rate without MAE
Time Frame
30 days post index-procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Unresectable malignant duodenal obstruction confirmed by biopsy Eligible for endoscopic intervention GOOSS score of 0 or 1 18 years of age or older Willing and able to comply with the study procedures or legally authorized representative (LAR) must provide written informed consent form (ICF) to participate in the study Exclusion Criteria: GOO symptoms are not expected to improve after the index procedure Life expectancy is about 3 months or less, which is not assumed applicable for surgical GJ Prior metallic stent placement for GOO Contraindicated to surgery and general anesthesia Neoplasm invading the target site of puncture in gastric and/or jejunum Abnormal coagulation INR > 1.5 and not correctable (per the discretion of the physician) or who require continuous complete anticoagulation Bleeding diathesis Altered anatomy of the upper gastrointestinal tract due to surgery of esophagus, stomach and duodenum that might preclude endoscopic drainage Presence of ileus caused by peritoneal carcinomatosis, or expected to present within 30 days post procedure Intervening gastric varices or vessels at the target site of stent insertion Ascites that may interfere the safety of the index procedure Biliary tract obstruction requiring treatment at the same day of the index procedure Allergic to any of the device materials Contraindications to use of electrosurgical devices Pregnancy, breastfeeding or intending to become pregnant during the study period Subject is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the study sponsor) Vulnerable subject Subject has other reason not to be eligible for this study per investigators' discretion Guidewire doesn't cross the area of GOO EP-DB doesn't advance to the target site in jejunum The distance between the gastric wall and jejunal wall when visualized on ultrasound after saline is introduced into the space between the two inflated balloons of EP-DB is deemed about 2 cm or more
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ryo Konishi
Phone
+81368537500
Email
JapanClinicalTrials@bsci.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Takao Itoi, MD
Organizational Affiliation
Tokyo Medical University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aichi Cancer Center Hospital
City
Nagoya
State/Province
Aichi
ZIP/Postal Code
4648681
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kazuo Hara, MD
Facility Name
Teine Keijinkai Hospital
City
Sapporo
State/Province
Hokkaido
ZIP/Postal Code
0060829
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Akio Katanuma, MD
Facility Name
Saitama Medical University International Medical Center
City
Hidaka
State/Province
Saitama
ZIP/Postal Code
3501241
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shomei Ryozawa, MD
Facility Name
The University of Tokyo Hospital
City
Bunkyō-Ku
State/Province
Tokyo
ZIP/Postal Code
1130033
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yousuke Nakai, MD
Facility Name
Cancer Institute Hospital of JFCR
City
Koto-Ku
State/Province
Tokyo
ZIP/Postal Code
1350063
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Naoki Sasahira, MD
Facility Name
Tokyo Medical University Hospital
City
Shinjuku-Ku
State/Province
Tokyo
ZIP/Postal Code
1600023
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Takao Itoi, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
The anonymized data and study protocol for this clinical trial may be made available to other researchers in accordance with Boston Scientific Data Sharing Policy: (http://www.bostonscientific.com/en-US/data-sharing-requests.html)

Learn more about this trial

Clinical Trial of EPASS With Hot AXIOS System

We'll reach out to this number within 24 hrs